SGP vs SLDB: fair value comparison
SpyGlass Pharma, Inc. and Solid Biosciences Inc. · Updated 2026-10-19
SGP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SLDB has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SGP currently ranks higher by quality score.
| SGP | SLDB | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $24.00 | $5.53 |
| 12-month range | $18.32–$26.86 | $3.93–$11.15 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #264 of 301 Healthcare | #266 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: SGP fair value analysis · SLDB fair value analysis